Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 185

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 185
---
 — | ​ |       — | ​ | —              | ​ |       57,961 | ​ |   740,461 |   |
| President and Chief Commercial Officer                 | ​ | 2023 | ​ | 350,000 | ​ | 280,000 | ​ |        70,000 | ​ | 123,125 | ​ | —              | ​ |       51,971 | ​ |   875,096 | ​ |
| Mitchell Arnold                                        | ​ | 2024 | ​ | 274,313 | ​ | 111,250 | ​ |             — | ​ |       — | ​ | —              | ​ |       52,729 | ​ |   438,292 | ​ |
| Vice President of Finance and Chief Accounting Officer | ​ | 2023 | ​ | 288,750 | ​ | 115,500 | ​ |             — | ​ |  22,578 | ​ | —              | ​ |       61,425 | ​ |   488,253 | ​ |

Mr. Boctor did not receive any stock awards in 2024.

110

For awards of stock options, the aggregate grant date fair value is computed based on the Black-Scholes option pricing model using the fair value of the underlying shares at the measurement date.

Amounts in this column reflect 401(k) contributions and insurance premiums (life, long term disability, short term disability, health, dental, and vision). For 2024, this represents: for Mr. Boctor, $10,350 for contributions under the Company’s 401(k) plan and $47,611 of insurance premiums; and for Mr. Arnold, $10,350 for contributions under the Company’s 401(k) plan and $42,379 of insurance premiums. For 2023, this represents: for Mr. Boctor, $6,584 for contributions under the Company’s 401(k) plan and $45,387 of insurance premiums; and for Mr. Arnold, $9,900 for contributions under the Company’s 401(k) plan and $51,525 of insurance premiums.

Employment Agreements

Fady Boctor

On January 24, 2019, the Company provided an offer letter to Mr. Boctor. The offer letter provided for Mr. Boctor’s at-will employment and set forth his initial base salary as $250,000 per annum ($208,333 was paid pro-rata based on